AIM Vaccine Yönetim

Yönetim kriter kontrolleri 3/4

AIM Vaccine CEO'su Yan Zhou, Sep2020 tarihinde atandı, in görev süresi 4.17 yıldır. in toplam yıllık tazminatı CN¥ 2.18M olup, şirket hissesi ve opsiyonları dahil olmak üzere 86.5% maaş ve 13.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 16.62% ine doğrudan sahiptir ve bu hisseler HK$ 1.32B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.5 yıl ve 4.3 yıldır.

Anahtar bilgiler

Yan Zhou

İcra Kurulu Başkanı

CN¥2.2m

Toplam tazminat

CEO maaş yüzdesi	86.5%
CEO görev süresi	4.2yrs
CEO sahipliği	16.6%
Yönetim ortalama görev süresi	3.5yrs
Yönetim Kurulu ortalama görev süresi	4.3yrs

Son yönetim güncellemeleri

Recent updates

Here's Why AIM Vaccine (HKG:6660) Can Afford Some Debt

Nov 15

Why Investors Shouldn't Be Surprised By AIM Vaccine Co., Ltd.'s (HKG:6660) 27% Share Price Plunge

Aug 24

It's A Story Of Risk Vs Reward With AIM Vaccine Co., Ltd. (HKG:6660)

May 29

Investor Optimism Abounds AIM Vaccine Co., Ltd. (HKG:6660) But Growth Is Lacking

Jun 09

CEO Tazminat Analizi

Yan Zhou'un ücretlendirmesi AIM Vaccine'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CN¥1b
Mar 31 2024	n/a	n/a	-CN¥1b
Dec 31 2023	CN¥2m	CN¥2m	-CN¥1b
Sep 30 2023	n/a	n/a	-CN¥913m
Jun 30 2023	n/a	n/a	-CN¥525m
Mar 31 2023	n/a	n/a	-CN¥422m
Dec 31 2022	CN¥2m	CN¥2m	-CN¥320m
Dec 31 2021	CN¥899m	CN¥1m	-CN¥693m

Tazminat ve Piyasa: Yan 'nin toplam tazminatı ($USD 300.08K ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 480.33K ).

Tazminat ve Kazançlar: Yan şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Yan Zhou (57 yo)

4.2yrs

Görev süresi

CN¥2,175,000

Tazminat

Mr. Yan Zhou is Executive Chairman and Chief Executive Officer of AIM Vaccine Co., Ltd. September 2020. He has served as a Director of AIM Vaccine Co., Ltd.since May 2015 and was re-designated as an execu...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yan Zhou	Executive Chairman & CEO	4.2yrs	CN¥2.18m	16.62% HK$ 1.3b
Xin Zhou	Executive Vice-Chairman & Executive President	11.5yrs	Veri yok	3.3% HK$ 262.4m
Wen Guan	Vice-Chairman of the Board & Executive President	3.8yrs	CN¥2.23m	Veri yok
Jie Zhou	Executive Director & Executive President	less than a year	Veri yok	3.3% HK$ 262.4m
Shaojun Jia	COO, Executive President & Executive Director	3.8yrs	CN¥2.43m	0.84% HK$ 66.6m
Lixin Niu	Chief Financial Officer	9.1yrs	Veri yok	Veri yok
Ling Liu	Secretary & Chief Investment Officer	9yrs	Veri yok	Veri yok
Zhang Fan	Chief Research Officer	3.7yrs	Veri yok	Veri yok
Meng Li	Chief Quality Officer	2.6yrs	Veri yok	Veri yok
Zhou Wenjuan	Chief Public Affairs Officer	2.7yrs	Veri yok	Veri yok
Lin Zhenyu	Chief Marketing Officer	2.7yrs	Veri yok	Veri yok
Wing Chi Lam	Joint Company Secretary	3.4yrs	Veri yok	Veri yok

3.5yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: 6660 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yan Zhou	Executive Chairman & CEO	9.5yrs	CN¥2.18m	16.62% HK$ 1.3b
Xin Zhou	Executive Vice-Chairman & Executive President	11.5yrs	Veri yok	3.3% HK$ 262.4m
Wen Guan	Vice-Chairman of the Board & Executive President	3.8yrs	CN¥2.23m	Veri yok
Jie Zhou	Executive Director & Executive President	9.5yrs	Veri yok	3.3% HK$ 262.4m
Shaojun Jia	COO, Executive President & Executive Director	7.3yrs	CN¥2.43m	0.84% HK$ 66.6m
Ker Wei Pei	Independent Non-Executive Director	4.2yrs	CN¥300.00k	Veri yok
Tingfeng Song	Chairman of The Supervisory Committee	3.8yrs	Veri yok	Veri yok
Hui Ouyang	Independent Non-Executive Director	3.5yrs	CN¥300.00k	Veri yok
Aijun Wang	Non-Executive Director	7.2yrs	Veri yok	4.13% HK$ 328.0m
Xiaoguang Guo	Independent Non-Executive Director	3.8yrs	CN¥300.00k	Veri yok
Jichen Zhao	Non-Executive Director	4.4yrs	Veri yok	Veri yok
Jie Wen	Independent Non-Executive Director	3.5yrs	CN¥300.00k	Veri yok

4.3yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 6660 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

AIM Vaccine Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

AIM Vaccine Co., Ltd. Announces Re-Designation of Directors

AIM Vaccine Co., Ltd., Annual General Meeting, May 20, 2024

AIM Vaccine Co., Ltd. Announces Executive Changes

AIM Vaccine Co., Ltd. Announces Board Appointments

Executive Chairman & CEO recently bought HK$249k worth of stock

Executive Chairman & CEO recently bought HK$716k worth of stock

Recent updates

Here's Why AIM Vaccine (HKG:6660) Can Afford Some Debt

AIM Vaccine Co., Ltd. Announces 13-Valent Pneumonia Conjugate Vaccine: Phase III Clinical Trials Completed, Production License Obtained and Application for Drug Marketing Registration Duly Submitted

AIM Vaccine Co., Ltd. Obtains Approval of the Clinical Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine

AIM Vaccine Co., Ltd. Announces Unblinding of Data from Phase III Clinical Trial of Iterative Serum-Free Rabies Vaccine

New minor risk - Share price stability

First half 2024 earnings released: CN¥0.12 loss per share (vs CN¥0.21 loss in 1H 2023)

AIM Vaccine Co., Ltd. Announces Submission of Official Application for Clinical Trials for Absorbed Tetanus Vaccine

AIM Vaccine Co., Ltd. Announces Re-Designation of Directors

Why Investors Shouldn't Be Surprised By AIM Vaccine Co., Ltd.'s (HKG:6660) 27% Share Price Plunge

AIM Vaccine Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Aim Vaccine Co., Ltd. Announces Submission of Pre-Applications for Clinical Trials for Two mRNA Vaccines of Respiratory Syncytial Virus (RSV) And Shingles/Herpes Zoster of Aim Vaccine

It's A Story Of Risk Vs Reward With AIM Vaccine Co., Ltd. (HKG:6660)

AIM Vaccine Co., Ltd., Annual General Meeting, May 20, 2024

Full year 2023 earnings released: CN¥1.07 loss per share (vs CN¥0.27 loss in FY 2022)

AIM Vaccine Co., Ltd. Submits the Pre- Application for Clinical Trials for quadrivalent influenza virus vaccine (MDCK Cells)

AIM Vaccine Co., Ltd. Submits Pre-Application for Clinical Trials for Novel-Process Highly-Effective Human Diploid Rabies Vaccine

New minor risk - Financial data availability

AIM Vaccine Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

New minor risk - Share price stability

AIM Vaccine Co., Ltd. Announces Completion of Application for Marketing of 13-Valent Pneumonia Conjugate Vaccine, Iterative Serum-Free Rabies Vaccine and 23-Valent Pneumonia Polysaccharide Vaccine

AIM Vaccine Co., Ltd. Submits the Pre- Application for Marketing Registration for Its 13-Valent Pneumonia Conjugate Vaccine

AIM Vaccine Co., Ltd. Announces Executive Changes

AIM Vaccine Co., Ltd. Announces Board Appointments

Executive Chairman & CEO recently bought HK$249k worth of stock

Executive Chairman & CEO recently bought HK$716k worth of stock

Executive Chairman & CEO recently bought HK$525k worth of stock

Executive Chairman & CEO recently bought HK$1.3m worth of stock

Aim Vaccine Co., Ltd. Announces Phase III Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine Is Near Completion and Statistical Unblinding Will Commence Soon

AIM Vaccine Co., Ltd. Announces Completion of Full Course of Vaccination in Subjects of Phase III Clinical Trial of 23-Valent Pneumococcal Polysaccharide Vaccine

New minor risk - Share price stability

Aim Vaccine Co., Ltd. Announces Phase III Clinical Trial of Serum-Free Rabies Vaccine Acciedated Satisfactory Phase Results

AIM Vaccine Co., Ltd. Announces Initiation of Randomized, Blinded and Compatible Vaccine-Controlled Phase III Clinical Trial of 23-Valent Pneumococcal Polysaccharide Vaccine

AIM Vaccine Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

AIM Vaccine Co., Ltd. Announces Bivalent mRNA Vaccine Against COVID-19 Variants Delta and OmicronBA.5 Obtains Clinical Trial Approval from National Medical Products Administration of China

AIM Vaccine Co., Ltd. Announces PRC National Medical Products Administration Accepts Application for Clinical Trial of Human Rabies mRNA Vaccine Against Rabies Virus

Investor Optimism Abounds AIM Vaccine Co., Ltd. (HKG:6660) But Growth Is Lacking

AIM Vaccine Co., Ltd. Announces Major Results of a Study on Protective Efficacy of COVID-19 Variant Omicron BA.5 mRNA Vaccine LVRNA012

Full year 2022 earnings released: CN¥0.27 loss per share (vs CN¥0.60 loss in FY 2021)

Aim Vaccine Co., Ltd. Announces That Mrna Covid-19 Vaccine Candidates Against Covid-19Variants and Original Strain Obtained Clinicaltrial Approvals in Pakistan

Less than half of directors are independent

AIM Kanghuai Biopharmaceutical (Jiangsu) Co., Ltd. Obtains Clinical Trial Approval for EV71-CA16 Bivalent HFMD Vaccine Candidate Issued by the Center for Drug Evaluation of National Medical Products Administration

AIM Vaccine Co., Ltd. has completed an IPO in the amount of HKD 156.97824 million.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş